Table 3.
Summary of main patient characteristics and results.
| Patients N | 39 |
| M/F | 27/12 |
| Age median (range) | 64 (48–84) |
| Study period | December 2018–October 2020 |
| Disease status: | |
| Relapse | 19 |
| Dara Schedule: | |
| DRd | 10 |
| DVd | 4 |
| Dara alone | 4 |
| DPd | 1 |
| Consolidation (DART4MM) | 20 |
| IRR at first infusion | 13/39 (33%) |
| Grade 1–2 | 13 (100%) |
| Allergic rhinitis/nasal congestion | 7 (54%) |
| Dyspnoea | 3 (13%) |
| Chills | 3 (13%) |
| Total N. Rapid infusions | 484 |
| Median N. rapid infusions per patient (range) | 14 (1-30) |
| N. Patients starting Dara Rapid since Third infusion | 30/39 |
| IRR in rapid infusions | 0/484 |